Report cover image

Nucleic Acids for Molecular Diagnosis Industry Research Report 2025

Publisher APO Research, Inc.
Published Feb 05, 2025
Length 117 Pages
SKU # APRC19588734

Description

Summary

According to APO Research, The global Nucleic Acids for Molecular Diagnosis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Nucleic Acids for Molecular Diagnosis include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Nucleic Acids for Molecular Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acids for Molecular Diagnosis.
The Nucleic Acids for Molecular Diagnosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acids for Molecular Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Nucleic Acids for Molecular Diagnosis Segment by Company

Agilent Technologies, Inc.
Aji Bio-Pharma
Bio-synthesis Inc.
Danaher Corporation
Eurofins Scientific SE
Integrated DNA Technologies
Kaneka Eurogentec S.A.
L.G.C Biosearch Technologies
Merck KGaA
metabion
QIAGEN
Thermo Fisher Scientific Inc.
Hongene
Synthgene
Nucleic Acids for Molecular Diagnosis Segment by Type

DNA Series
RNA Series
Nucleic Acids for Molecular Diagnosis Segment by Application

Early Cancer Screening
Genetic Diseases
Blood Screening
Genome Sequencing
Infectious Diseases
Other
Nucleic Acids for Molecular Diagnosis Segment by Application

Early Cancer Screening
Genetic Diseases
Blood Screening
Genome Sequencing
Infectious Diseases
Other
Nucleic Acids for Molecular Diagnosis Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Acids for Molecular Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nucleic Acids for Molecular Diagnosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

117 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Nucleic Acids for Molecular Diagnosis by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 DNA Series
2.2.3 RNA Series
2.3 Nucleic Acids for Molecular Diagnosis by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Early Cancer Screening
2.3.3 Genetic Diseases
2.3.4 Blood Screening
2.3.5 Genome Sequencing
2.3.6 Infectious Diseases
2.3.7 Other
2.4 Assumptions and Limitations
3 Nucleic Acids for Molecular Diagnosis Breakdown Data by Type
3.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Type (2020-2025)
3.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Type (2026-2031)
4 Nucleic Acids for Molecular Diagnosis Breakdown Data by Application
4.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Application (2020-2025)
4.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Nucleic Acids for Molecular Diagnosis Market Perspective (2020-2031)
5.2 Global Nucleic Acids for Molecular Diagnosis Growth Trends by Region
5.2.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Nucleic Acids for Molecular Diagnosis Historic Market Size by Region (2020-2025)
5.2.3 Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Region (2026-2031)
5.3 Nucleic Acids for Molecular Diagnosis Market Dynamics
5.3.1 Nucleic Acids for Molecular Diagnosis Industry Trends
5.3.2 Nucleic Acids for Molecular Diagnosis Market Drivers
5.3.3 Nucleic Acids for Molecular Diagnosis Market Challenges
5.3.4 Nucleic Acids for Molecular Diagnosis Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue
6.1.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue (2020-2025)
6.1.2 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Players (2020-2025)
6.2 Global Nucleic Acids for Molecular Diagnosis Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Nucleic Acids for Molecular Diagnosis Head Office and Area Served
6.4 Global Nucleic Acids for Molecular Diagnosis Players, Product Type & Application
6.5 Global Nucleic Acids for Molecular Diagnosis Manufacturers Established Date
6.6 Global Nucleic Acids for Molecular Diagnosis Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
7.2 North America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
7.4 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
8.2 Europe Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
8.4 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
9.2 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
9.4 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
10.2 South America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
10.4 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
11.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
11.4 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Agilent Technologies, Inc.
12.1.1 Agilent Technologies, Inc. Company Information
12.1.2 Agilent Technologies, Inc. Business Overview
12.1.3 Agilent Technologies, Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.1.5 Agilent Technologies, Inc. Recent Developments
12.2 Aji Bio-Pharma
12.2.1 Aji Bio-Pharma Company Information
12.2.2 Aji Bio-Pharma Business Overview
12.2.3 Aji Bio-Pharma Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
12.2.5 Aji Bio-Pharma Recent Developments
12.3 Bio-synthesis Inc.
12.3.1 Bio-synthesis Inc. Company Information
12.3.2 Bio-synthesis Inc. Business Overview
12.3.3 Bio-synthesis Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.3.5 Bio-synthesis Inc. Recent Developments
12.4 Danaher Corporation
12.4.1 Danaher Corporation Company Information
12.4.2 Danaher Corporation Business Overview
12.4.3 Danaher Corporation Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
12.4.5 Danaher Corporation Recent Developments
12.5 Eurofins Scientific SE
12.5.1 Eurofins Scientific SE Company Information
12.5.2 Eurofins Scientific SE Business Overview
12.5.3 Eurofins Scientific SE Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
12.5.5 Eurofins Scientific SE Recent Developments
12.6 Integrated DNA Technologies
12.6.1 Integrated DNA Technologies Company Information
12.6.2 Integrated DNA Technologies Business Overview
12.6.3 Integrated DNA Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.6.5 Integrated DNA Technologies Recent Developments
12.7 Kaneka Eurogentec S.A.
12.7.1 Kaneka Eurogentec S.A. Company Information
12.7.2 Kaneka Eurogentec S.A. Business Overview
12.7.3 Kaneka Eurogentec S.A. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.7.5 Kaneka Eurogentec S.A. Recent Developments
12.8 L.G.C Biosearch Technologies
12.8.1 L.G.C Biosearch Technologies Company Information
12.8.2 L.G.C Biosearch Technologies Business Overview
12.8.3 L.G.C Biosearch Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.8.5 L.G.C Biosearch Technologies Recent Developments
12.9 Merck KGaA
12.9.1 Merck KGaA Company Information
12.9.2 Merck KGaA Business Overview
12.9.3 Merck KGaA Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio
12.9.5 Merck KGaA Recent Developments
12.10 metabion
12.10.1 metabion Company Information
12.10.2 metabion Business Overview
12.10.3 metabion Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio
12.10.5 metabion Recent Developments
12.11 QIAGEN
12.11.1 QIAGEN Company Information
12.11.2 QIAGEN Business Overview
12.11.3 QIAGEN Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio
12.11.5 QIAGEN Recent Developments
12.12 Thermo Fisher Scientific Inc.
12.12.1 Thermo Fisher Scientific Inc. Company Information
12.12.2 Thermo Fisher Scientific Inc. Business Overview
12.12.3 Thermo Fisher Scientific Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.12.5 Thermo Fisher Scientific Inc. Recent Developments
12.13 Hongene
12.13.1 Hongene Company Information
12.13.2 Hongene Business Overview
12.13.3 Hongene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.13.5 Hongene Recent Developments
12.14 Synthgene
12.14.1 Synthgene Company Information
12.14.2 Synthgene Business Overview
12.14.3 Synthgene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.14.5 Synthgene Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Nucleic Acids for Molecular Diagnosis Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Type (2020-2025)
Table 7. Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Type (2026-2031)
Table 9. Global Nucleic Acids for Molecular Diagnosis Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Application (2020-2025)
Table 11. Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Application (2026-2031)
Table 13. Global Nucleic Acids for Molecular Diagnosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Nucleic Acids for Molecular Diagnosis Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Nucleic Acids for Molecular Diagnosis Market Share by Region (2020-2025)
Table 16. Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Nucleic Acids for Molecular Diagnosis Market Share by Region (2026-2031)
Table 18. Nucleic Acids for Molecular Diagnosis Industry Trends
Table 19. Nucleic Acids for Molecular Diagnosis Industry Drivers
Table 20. Nucleic Acids for Molecular Diagnosis Industry Opportunities and Challenges
Table 21. Nucleic Acids for Molecular Diagnosis Market Restraints
Table 22. Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Players (2020-2025)
Table 24. Global Nucleic Acids for Molecular Diagnosis Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Nucleic Acids for Molecular Diagnosis, Headquarters and Area Served
Table 26. Global Nucleic Acids for Molecular Diagnosis Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Nucleic Acids for Molecular Diagnosis by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Nucleic Acids for Molecular Diagnosis Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031) & (US$ Million)
Table 45. Company One Company Information
Table 46. Company One Business Overview
Table 47. Company One Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 48. Company One Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 49. Company One Recent Developments
Table 50. Company Two Company Information
Table 51. Company Two Business Overview
Table 52. Company Two Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 53. Company Two Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 54. Company Two Recent Developments
Table 55. Company Three Company Information
Table 56. Company Three Business Overview
Table 57. Company Three Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 58. Company Three Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 59. Company Three Recent Developments
Table 60. Company Four Company Information
Table 61. Company Four Business Overview
Table 62. Company Four Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 63. Company Four Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 64. Company Four Recent Developments
Table 65. Company Five Company Information
Table 66. Company Five Business Overview
Table 67. Company Five Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 68. Company Five Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 69. Company Five Recent Developments
Table 70. Company Six Company Information
Table 71. Company Six Business Overview
Table 72. Company Six Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 73. Company Six Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 74. Company Six Recent Developments
Table 75. Company Seven Company Information
Table 76. Company Seven Business Overview
Table 77. Company Seven Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 78. Company Seven Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 79. Company Seven Recent Developments
Table 80. Company Eight Company Information
Table 81. Company Eight Business Overview
Table 82. Company Eight Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 83. Company Eight Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 84. Company Eight Recent Developments
Table 85. Company Nine Company Information
Table 86. Company Nine Business Overview
Table 87. Company Nine Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 88. Company Nine Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 89. Company Nine Recent Developments
Table 90. Company Ten Company Information
Table 91. Company Ten Business Overview
Table 92. Company Ten Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 93. Company Ten Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 94. Company Ten Recent Developments
Table 95. Company 11 Company Information
Table 96. Company 11 Business Overview
Table 97. Company 11 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 98. Company 11 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 99. Company 11 Recent Developments
Table 100. Company 12 Company Information
Table 101. Company 12 Business Overview
Table 102. Company 12 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 103. Company 12 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 104. Company 12 Recent Developments
Table 105. Company 13 Company Information
Table 106. Company 13 Business Overview
Table 107. Company 13 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 108. Company 13 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 109. Company 13 Recent Developments
Table 110. Company 14 Company Information
Table 111. Company 14 Business Overview
Table 112. Company 14 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 113. Company 14 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 114. Company 14 Recent Developments
Table 115. Company 15 Company Information
Table 116. Company 15 Business Overview
Table 117. Company 15 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 118. Company 15 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 119. Company 15 Recent Developments
Table 120. Company 16 Company Information
Table 121. Company 16 Business Overview
Table 122. Company 16 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 123. Company 16 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 124. Company 16 Recent Developments
Table 125. Company 17 Company Information
Table 126. Company 17 Business Overview
Table 127. Company 17 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 128. Company 17 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 129. Company 17 Recent Developments
Table 130. Company 18 Company Information
Table 131. Company 18 Business Overview
Table 132. Company 18 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 133. Company 18 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 134. Company 18 Recent Developments
Table 135. Company 19 Company Information
Table 136. Company 19 Business Overview
Table 137. Company 19 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 138. Company 19 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 139. Company 19 Recent Developments
Table 140. Company 20 Company Information
Table 141. Company 20 Business Overview
Table 142. Company 20 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 143. Company 20 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 144. Company 20 Recent Developments
Table 145. Company 21 Company Information
Table 146. Company 21 Business Overview
Table 147. Company 21 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 148. Company 21 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 149. Company 21 Recent Developments
Table 150. Company 22 Company Information
Table 151. Company 22 Business Overview
Table 152. Company 22 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 153. Company 22 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 154. Company 22 Recent Developments
Table 155. Company 23 Company Information
Table 156. Company 23 Business Overview
Table 157. Company 23 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 158. Company 23 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 159. Company 23 Recent Developments
Table 160. Company 24 Company Information
Table 161. Company 24 Business Overview
Table 162. Company 24 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 163. Company 24 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 164. Company 24 Recent Developments
Table 165. Company 25 Company Information
Table 166. Company 25 Business Overview
Table 167. Company 25 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 168. Company 25 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 169. Company 25 Recent Developments
Table 170. Company 26 Company Information
Table 171. Company 26 Business Overview
Table 172. Company 26 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 173. Company 26 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 174. Company 26 Recent Developments
Table 175. Company 27 Company Information
Table 176. Company 27 Business Overview
Table 177. Company 27 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 178. Company 27 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 179. Company 27 Recent Developments
Table 180. Company 28 Company Information
Table 181. Company 28 Business Overview
Table 182. Company 28 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 183. Company 28 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 184. Company 28 Recent Developments
Table 185. Company 29 Company Information
Table 186. Company 29 Business Overview
Table 187. Company 29 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 188. Company 29 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 189. Company 29 Recent Developments
Table 190. Company 30 Company Information
Table 191. Company 30 Business Overview
Table 192. Company 30 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 193. Company 30 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 194. Company 30 Recent Developments
Table 195. Company 31 Company Information
Table 196. Company 31 Business Overview
Table 197. Company 31 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 198. Company 31 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 199. Company 31 Recent Developments
Table 200. Company 32 Company Information
Table 201. Company 32 Business Overview
Table 202. Company 32 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 203. Company 32 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 204. Company 32 Recent Developments
Table 205. Company 33 Company Information
Table 206. Company 33 Business Overview
Table 207. Company 33 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 208. Company 33 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 209. Company 33 Recent Developments
Table 210. Company 34 Company Information
Table 211. Company 34 Business Overview
Table 212. Company 34 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 213. Company 34 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 214. Company 34 Recent Developments
Table 215. Company 35 Company Information
Table 216. Company 35 Business Overview
Table 217. Company 35 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 218. Company 35 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 219. Company 35 Recent Developments
Table 220. Company 36 Company Information
Table 221. Company 36 Business Overview
Table 222. Company 36 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 223. Company 36 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 224. Company 36 Recent Developments
Table 225. Company 37 Company Information
Table 226. Company 37 Business Overview
Table 227. Company 37 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 228. Company 37 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 229. Company 37 Recent Developments
Table 230. Company 38 Company Information
Table 231. Company 38 Business Overview
Table 232. Company 38 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 233. Company 38 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 234. Company 38 Recent Developments
Table 235. Company 39 Company Information
Table 236. Company 39 Business Overview
Table 237. Company 39 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 238. Company 39 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 239. Company 39 Recent Developments
Table 240. Company 40 Company Information
Table 241. Company 40 Business Overview
Table 242. Company 40 Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025) & (US$ Million)
Table 243. Company 40 Nucleic Acids for Molecular Diagnosis Product Portfolio
Table 244. Company 40 Recent Developments
Table 245. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Nucleic Acids for Molecular Diagnosis Product Image
Figure 5. Global Nucleic Acids for Molecular Diagnosis Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Nucleic Acids for Molecular Diagnosis Market Share by Type: 2024 VS 2031
Figure 7. DNA Series Product
Figure 8. RNA Series Product
Figure 9. Global Nucleic Acids for Molecular Diagnosis Market Size by Application (2025-2031) & (US$ Million)
Figure 10. Global Nucleic Acids for Molecular Diagnosis Market Share by Application: 2024 VS 2031
Figure 11. Early Cancer Screening Product
Figure 12. Genetic Diseases Product
Figure 13. Blood Screening Product
Figure 14. Genome Sequencing Product
Figure 15. Infectious Diseases Product
Figure 16. Other Product
Figure 17. Global Nucleic Acids for Molecular Diagnosis Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Nucleic Acids for Molecular Diagnosis Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Nucleic Acids for Molecular Diagnosis Market Share by Region: 2024 VS 2031
Figure 20. Global Nucleic Acids for Molecular Diagnosis Market Share by Players in 2024
Figure 21. Global Nucleic Acids for Molecular Diagnosis Manufacturers Established Date
Figure 22. Global Top 5 and 10 Nucleic Acids for Molecular Diagnosis Players Market Share by Revenue in 2024
Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. North America Nucleic Acids for Molecular Diagnosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Nucleic Acids for Molecular Diagnosis Market Share by Country (2020-2031)
Figure 26. United States Nucleic Acids for Molecular Diagnosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Nucleic Acids for Molecular Diagnosis Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Mexico Nucleic Acids for Molecular Diagnosis Market Share by Country (2020-2031)
Figure 29. Europe Nucleic Acids for Molecular Diagnosis Market Size YoY Growth (2020-2031) & (US$ Million)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us